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Increased expression of receptor for advanced glycation end products (RAGE) in adipose tissue has been associated with
inflammation, adipocyte hypertrophy, and impaired insulin signal. Epicardial adipose tissue (EAT), a visceral fat surrounding the
myocardium, is potentially involved in the onset/progression of coronary artery disease (CAD). To date, the role of RAGE in EAT
has not been exploredmuch.We examined whether the RAGE expression in EATwas associated with EAT adiposity andmetabolic
dysfunctions normally found in CAD patients. EAT samples were obtained from 33 patients undergoing open-heart surgery. EAT
expression of RAGE, GLUT4, adiponenctin, GLO1, HMGB1, TLR-4, and MyD88 was analyzed by microarray. EAT thickness was
quantified by echocardiography. Anthropometric measures and clinical parameters were taken. BMI, HOMA-IR, and LAP indices
were calculated. With increasing RAGE expression in EAT we observed increases in EAT thickness, reduced expression of GLUT4,
adiponectin, and GLO1, and elevations of HMGB1, TLR-4, and MyD88. There were significant correlations between RAGE and
EAT thickness and between RAGE and the genes. LAP was higher in patients with increased RAGE expression. Our data suggest
that in CAD patients RAGE may be involved in promoting EAT adiposity and metabolic dysfunction, such as impaired insulin
signaling.
1. Introduction
The role of epicardial adipose tissue (EAT) in the onset and
progression of coronary artery disease (CAD) is recognized
[1], but the mechanisms and mediators promoting and link-
ing EAT dysfunctions and CAD still need to be understood
and described better.
The receptor for advanced glycation end products
(RAGE) is a multiligand receptor that binds advanced glyca-
tion end products (AGE) and other endogenous nonglycated
peptides, such as ligand mobility group box 1 (HMGB1),
many of which are important regulators of the inflamma-
tory process [2]. Although RAGE was initially implicated
in cardiovascular complications related to diabetes [3, 4],
recent reports have suggested its central role in inflammation
and inflammation-associated dysfunctions, such as obesity,
metabolic syndrome, and atherosclerosis, even in nondia-
betic conditions [5–8].
In CAD, EAT displays inflammatory features due to
infiltrated macrophages and T cells and reduced production
of protective factors in favor of detrimental proinflammatory
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mediators. This inflammatory condition may in turn con-
tribute to the progression of atherosclerosis besides exacer-
bating metabolic complications in EAT [9, 10].
On the basis of the potential role of RAGE in adipogene-
sis, inflammation, and insulin resistance [5–8], we explored
whether its expression in EAT was associated with EAT
adiposity and the metabolic dysfunctions, such as impaired
insulin signaling, normally found in CAD patients.
2. Materials and Methods
2.1. Study Population. Thirty-three male CAD patients
undergoing coronary artery bypass grafting (CABG) surgery
were enrolled in the study during their hospitalization.
Exclusion criteria were acute myocardial infarction within
the last month, previous or current malignant disease, major
abdominal surgery within the previous 6 months, renal and
liver diseases, end-stage heart failure, and more than 3%
change in body weight in the previous threemonths. Anthro-
pometric measures were recorded. Body mass index (BMI)
was calculated by dividing the weight (in Kg) by the square
of the height (in meters). The study protocol, conducted
in accordance with the Declaration of Helsinki, as revised
in 2013, was approved by the local ethics committee (ASL
Milano Due, Protocol 2516). Patients gave their written
informed consent to the protocol.
2.2. Blood Collection. Blood samples were collected after
overnight fasting into pyrogen-free tubes with ethylene-
diaminetetraacetic acid as anticoagulant. Fasting glucose,
glycated hemoglobin, insulin, total and HDL cholesterol,
triglycerides, and C-reactive protein (CRP) were quantified
with commercial kits using Cobas 6000 analyzer (Roche
Diagnostics, Milan, Italy), as previously reported [11, 12].
Precision was determined by the manufacturer using human
samples and controls in an internal protocol with repeatabil-
ity (𝑛 = 21) and intermediate precision (3 aliquots per run, 1
run per day, 21 days). Results for repeatability were glucose,
1% at 98.8mg/dL and 0.9% at 245mg/dL; HbA1c, 1.3% at 5.3%
and 1.1% at 9.9%; insulin, 1.9% at 6.36 𝜇U/mL and 1.9% at
20.9𝜇U/mL; total cholesterol, 1.1% at 88.5mg/dL and 0.9% at
183mg/dL; HDL, 0.4% at 53.4mg/dL and 1% at 34.4mg/dL;
triglycerides, 0.9% at 125mg/dL and 0.8% at 212mg/dL; and
CRP, 1.2% at 3.35mg/L and 1.3% at 44.4mg/L.
Results for intermediate precision were glucose, 1.3%
at 96.9mg/dL and 1.1% at 241mg/dL; HbA1c, 1.4% at 5.3%
and 1.5% at 9.9%; insulin, 2.6% at 6.36 𝜇U/mL and 2.8% at
20.9𝜇U/mL; total cholesterol, 1.6% at 89.3mg/dL and 1.6% at
188mg/dL; HDL, 0.9% at 51.8mg/dL and 1.5% at 34mg/dL;
triglycerides, 2% at 123mg/dL and 1.6% at 206mg/dL; and
CRP, 2.9% at 29.1mg/L and 1.9% at 43.6mg/L.
LDL cholesterol was calculated with the Friedewald for-
mula. Insulin resistance index (HOMA-IR) was calculated as
follows: HOMA-IR = fasting insulin [𝜇U/mL] × fasting glu-
cose [mmol/L]/22.5. The formula used for the lipid accumu-
lation product (LAP) was (waist circumference [WC, cm] −
65) × (triglycerides [TG, mmol/L]).
2.3. Quantification of EAT. EAT quantification by echocar-
diography was performed in addition to the routine clinical
examinations just before CABG surgery, usually one or two
days before. Patients were examined by echocardiography
using an M-mode color-Doppler VSF (Vingmed-System
Five; General Electric, Horten, Norway) with a 2.5–3.5MHz
transducer probe. EAT thickness was measured as previously
reported [13].
2.4. EAT Collection. EAT biopsy samples were harvested
adjacent to the proximal right coronary artery prior to start-
ing cardiopulmonary bypass pumping. Samples were stored
in Allprotect Tissue Reagent (Qiagen, Hilden, Germany) at
−20∘C until RNA extraction.
2.5. RNA Extraction and Gene Expression Analysis. Total
RNA was extracted from tissue with the RNeasy Lipid
Tissue Kit according to the manufacturer’s procedures (Qia-
gen). RNA concentration was quantified by NanoDrop
2000 (Thermo Scientific, Wilmington, Germany) and RNA
integrity was assessed using the Agilent RNA 6000 Nano
Kit and the Agilent 2100 Bioanalyzer (Agilent Technologies,
Santa Clara, CA). Gene expression was analyzed with a one-
color microarray platform (Agilent): 50 ng of total RNA was
labeled with Cy3 using the Agilent Low Input Quick-Amp
Labeling Kit-1 color, according to the manufacturer’s direc-
tions. cRNA was purified with the RNeasy Mini Kit (Qiagen)
and the amount and labeling efficiency were measured with
NanoDrop. Hybridization was done using the Agilent Gene
Expression Hybridization Kit and scanning with the Agilent
G2565CAMicroarray Scanner System.
Data were processed using Agilent Feature Extraction
Software (10.7) with the single-color gene expression protocol
and raw data were analyzed with ChipInspector Software
(Genomatix, Munich, Germany). In brief, raw data were
normalized on a single-probe level based on the array mean
intensities and statistics were calculated using the SAM algo-
rithm by Tusher et al. [14]. Changes were determined from
normalized data.
2.6. Statistical Analysis. Data are expressed as mean ± SD or
number and percentage. The normality of data distribution
was assessed by the Kolmogorov-Smirnoff test. Quantitative
variables were compared using Student’s unpaired 𝑡-test and
Mann-Whitney and Kruskal-Wallis tests, as appropriate. The
𝜒
2 test was used for categorical variables. Relations between
parameters were examined by the Spearman correlation test.
Data were analyzed using GraphPad Prism 5.0 biochemical
statistical package (GraphPad Software, San Diego, CA). A 𝑝
value < 0.05 was considered significant.
3. Results
3.1. Patients. Demographic, anthropometric, and clinical
characteristics of the patients are shown in Table 1. Patients
were classified into two groups (Q1 and Q2) according to the
median value of RAGE expression in EAT (168.33 arbitrary
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Table 1: Demographic, anthropometric, and biochemical characteristics of coronary artery disease patients included in the study before and
after classification according to the median value of RAGE expression at EAT level (Q1 and Q2 groups).
Median 25th–75th percentiles Range Q1 (mean ± SD) Q2 (mean ± SD) 𝑝
Age (years) 68.00 57.50–71.70 50.00–86.00 68.18 ± 2.99 66.19 ± 2.09 0.67
Weight (Kg) 75.00 65.75–81.50 52.00–135.00 72.88 ± 2.84 84.17 ± 6.12 0.33
BMI (kg/m2) 26.20 23.76–27.90 19.12–41.80 25.14 ± 0.71 28.62 ± 1.44 0.08
Waist (cm) 102.00 93.50–109.05 72.00–144.00 95.94 ± 3.25 109.60 ± 3.61 <0.01
EAT thickness (mm) 7.50 5.78–8.00 3.00–10.00 5.50 ± 0.67 7.58 ± 0.44 <0.05
Fasting glucose (mg/dl) 82.50 77.50–104.50 64.00–177.00 99.24 ± 7.83 91.53 ± 6.59 0.79
Fasting insulin (𝜇U/ml) 7.11 4.17–10.93 3.19–45.06 6.97 ± 0.71 9.07 ± 1.90 0.53
HbA1C (%) 4.68 3.53–5.52 2.79–7.10 4.76 ± 0.36 4.58 ± 0.30 0.71
Total cholesterol (mg/dl) 153.00 138.00–180.30 88.00–261.00 169.80 ± 10.20 146.40 ± 6.81 0.08
HDL cholesterol (mg/dl) 44.00 34.25–49.25 23.00–69.00 44.13 ± 2.50 41.73 ± 3.53 0.58
LDL cholesterol (mg/dl) 83.60 71.50–109.30 17.60–192.00 104.40 ± 9.89 82.57 ± 4.45 0.07
Triglycerides (mg/dl) 107.00 88.50–143.00 64.00–244.00 114.60 ± 9.43 130.10 ± 15.57 0.40
CRP (mg/dl) 0.20 0.10–0.95 0.00–7.90 0.76 ± 0.37 1.23 ± 0.54 0.44
Systolic blood pressure (mmHg) 130.00 120.00–140.00 110.00–150.00 129.10 ± 2.51 131.30 ± 3.26 0.61
Diastolic blood pressure (mmHg) 70.00 70.00–80.00 60.00–80.00 74.55 ± 1.58 83.00 ± 1.49 0.10
𝑛 % Q1 (𝑛, %) Q2 (𝑛, %) 𝑝
Smokers 14 42.42 6, 42.85 8, 57.15 0.73
Diabetes mellitus 9 27.27 4, 44.44 5, 55.56 0.70
Hypertension 24 72.73 11, 45.83 13, 54.17 0.44
Dyslipidemia 20 60.61 7, 35.00 13, 65.00 <0.05
Aspirin 19 57.58 6, 31.58 13, 68.42 <0.05
Antidiabetics 6 18.18 3, 50.00 3, 50.00 1
ACEI/ARB 24 72.73 10, 41.67 14, 58.33 0.12
𝛽-Blockers 16 48.48 7, 43.75 9, 56.25 0.49
Calcium channel blockers 6 18.18 3, 50.00 3, 50.00 1
Statins 22 66.67 8, 36.36 14, 63.64 <0.05
ACEI: angiotensinogen-converting enzyme inhibitor; ARB: angiotensin receptor blockade; BMI: body mass index; CRP: C-reactive protein; EAT: epicardial
adipose tissue; HbA1C: glycated hemoglobin. Data are expressed as median, 25th–75th percentiles and range or number (𝑛), and % or mean ± standard
deviation (SD).
unit, A.U.). Patients were 17 in Q1 and 16 in Q2 and the
mean value of RAGE expression was 140.29A.U. in Q1 and
233.33 A.U. in Q2 (𝑝 < 0.001). No statistically significant
differences were observed in clinical parameters between the
two groups. There were higher percentages of dyslipidemic
patients andmore patients taking statin and aspirin in the Q2
group (𝑝 < 0.05 for all).
3.2. Increased RAGE Expression in EAT Is Associated with
Greater Echocardiographic EAT Thickness and Higher Adi-
posity Indices. Echocardiographic EAT thickness and WC, a
marker of visceral fat distribution, were higher in group Q2
than Q1 (𝑝 < 0.05 and 𝑝 < 0.01, resp.) (Figure 1(a) and
Table 1). Positive correlations were seen between RAGE-EAT
thickness (𝑟 = 0.48, 𝑝 < 0.05) and RAGE-WC (𝑟 = 0.35, 𝑝 <
0.05) (Figure 1(b)). The relation between increased RAGE
expression and greater EAT thickness was confirmed by
classifying patients according to the median EAT thickness
(7.5mm). RAGE expression in the upper group (EAT thick-
ness > 7.5mm) was about 1.3 times higher (𝑝 < 0.05) than in
the lower group (EAT thickness < 7.5mm) (Figure 1(c)).
3.3. Increased RAGE Expression in EAT Is Associated with
Lower GLUT4 and Adiponectin Expression and a Higher LAP
Index. Patients in the upper group of RAGE expression in
EAT (Q2) had about 1.6 times lower levels of both the insulin-
sensitizing adipokine adiponectin and the insulin-responsive
glucose transporter 4 (GLUT4) than in the Q1 group (𝑝 <
0.05 for both) (Figure 2). There was an inverse correlation
between RAGE-adiponectin (𝑟 = −0.40, 𝑝 < 0.05) and
RAGE-GLUT4 (𝑟 = −0.60, 𝑝 < 0.001).
Examining the relation between RAGE expression in
EAT and LAP and HOMA-IR, two parameters of insulin
resistance, only LAP was higher in Q2 than in Q1 (Figure 2).
3.4. Increased RAGE Expression in EAT Is Associated with
Lower Expression of the Antioxidant Glyoxalase 1 System and
HigherHMGB1, TLR-4, andMyD88. Patients in theQ2 group
of RAGE expression in EAT had about a 1.3 times lower level
of glyoxalase 1 (GLO1), a system playing a critical role in the
prevention of glycation reactions mediated by methylglyoxal,
glyoxal, and other RAGE ligands, and about 1.2 times the level
of the endogenous RAGE ligand HMGB1 compared to group
Q1 (𝑝 < 0.01 for both) (Figure 3(a)). Both TLR-4 andMyD88,
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Figure 1: Relationship between RAGE expression in EAT, EAT thickness, and anthropometric indices in CAD patients. (a) CAD patients
were stratified into two groups (Q1 and Q2) on the basis of the median RAGE expression in EAT, and EAT thickness, waist circumference,
and BMI were compared in the two groups. (b) Spearman correlation analysis between mRNA RAGE level in EAT and waist circumference
and EAT thickness. (c) CAD patients were stratified into two groups (Q1 and Q2) on the basis of the median EAT thickness (7.5mm) and the
levels of RAGE expression were compared in the two groups. A.U.: arbitrary unit. Data are expressed as mean ± SD; ∗𝑝 < 0.05, ∗∗𝑝 < 0.01.






































Figure 2: Relationship between RAGE expression in EAT and indices of insulin sensitivity. CAD patients were stratified into two groups (Q1
and Q2) on the basis of the median RAGE expression in EAT. (a) Gene expression of GLUT4 and adiponectin in EAT was compared in the
two groups. (b) HOMA-IR and LAP were compared in the two groups. Data are expressed as mean ± SD; ∗𝑝 < 0.05.
important in the activation of the innate immune system,
were higher in group Q2 (about 1.4 times, 𝑝 < 0.05 for both)
(Figure 3(b)).
Correlation analyses indicated an inverse correlation
between RAGE and GLO1 (𝑟 = −0.65, 𝑝 < 0.0001) and a pos-
itive association between RAGE-TLR-4 (𝑟 = 0.51, 𝑝 < 0.001)
and RAGE-MyD88 (𝑟 = 0.48, 𝑝 < 0.01).
4. Discussion
To the best of our knowledge this is the first human study
exploring the existence of an association between the expres-
sion of RAGE in EAT, EAT metabolic dysfunctions, and
adiposity in CAD patients. The findings indicate that EAT
thickness as well as local tissue inflammation and insulin
sensitivity seems related to local expression of RAGE.
Previous in vitro and animal studies suggested that RAGE
could be involved in the progression of obesity, with a direct
role in promoting adipocyte hypertrophy [7]. RAGE−/−mice
at 20 weeks of age had lower weight and lower epididymal
adipose tissue weight and adipocyte size than wild type mice
[7].The observation that adenoviral RAGE overexpression in
3T3-L1 adipocytes markedly induced a hypertrophic pheno-
type, which was suppressed by RAGE silencing, also supports
a role for RAGE in promoting adipocyte hypertrophy [7].
Our data seem to confirm that RAGE is involved in adi-
posity,mainly visceral, in humans too. In fact, with increasing
local expression of RAGE, we observed increases in the thick-
ness of EAT, an acknowledged visceral fat, and inWC, which
serves as a marker of visceral fat accumulation. Whether this
RAGE-related EAT expansion involved adipocyte hypertro-
phy needs to be explored further. In fact, we noted a hyper-
trophic state associated with the increased RAGE expression
(data not shown), but since the number of patients with
enough tissue for this analysis was limited, these results can
only be considered preliminary.
In this study we did not directly explore the mechanisms
promoting RAGE upregulation, but on the basis of previous
data also from our group it would appear that both the
increased inflammatory state described in EAT in CAD
patients and the greater local accumulation of AGE products
in expanding adipose tissue may promote this [9, 12, 15–17].
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Figure 3: Relationship between RAGE expression in EAT and EAT inflammation. CAD patients were stratified into two groups (Q1 and Q2)
on the basis of the median RAGE expression in EAT. (a) Gene expression of GLO1 and HMGB1 in EAT was compared in the two groups; (b)
TLR-4 and MyD88 levels were compared in the two groups. A.U.: arbitrary unit. Data are expressed as mean ± SD; ∗𝑝 < 0.05.
The increase in the local production of damaging agents and
reduced protection against them is also borne out by the
marked reduction in GLO1, the major detoxification enzyme
that protects against AGE [18], and the higher expression
of HMGB1, an endogenous mediator of inflammation able
to bind RAGE, promoting its expression and amplifying
the inflammatory response also through activation of toll-
like receptor (TLR)/MyD88 pathways. It has recently been
suggested that RAGEnot only shares several common ligands
with the TLRs, such as HMGB1, but may also interact with
MyD88, an important intracellular adaptor protein used by
these receptors [19]. There is increasing evidence, therefore,
of their potential synergism in amplifying inflammatory
responses and our findings too suggest a link between TLR-
4/MyD88 and RAGE hyperexpression.
Our data also confirm that some important metabolic
dysfunctions of EAT in patients with CAD may be related
to RAGE overexpression. Monden et al. [7] indicated that
RAGE overexpression reduced the genes involved in insulin
sensitivity, such as GLUT4 and adiponectin, and attenuated
insulin function.We too saw lower levels of both GLUT4 and
adiponectin, with increased RAGE expression in EAT. This
suggests a potential impairment of local insulin signaling.We
examined insulin sensitivity in our CAD patients using the
HOMA-IR, a marker of insulin resistance mainly in the liver,
and LAP, a continuous variable based onWC and triglyceride
concentration, two parameters which reflect tissue lipid
accumulation and denote visceral adiposity [20, 21]. Our
observation that RAGE expression in EATwasmainly related
to LAP reinforced the idea of a strong correlation between
local RAGE overexpression, fat accumulation, and impaired
insulin sensitivity.
Our study has some limitations. The first one is the lack
of data on protein expression. Since isolation of EAT during
surgery is a delicate and difficult procedure and the amount
of tissue isolated is often poor and not enough to perform
both gene and protein expression analyses, in this study we
first decided to carry out a gene expression study. The lack of
quantification of local AGE as well as the evaluation of other
molecules, whichmay promote RAGEupregulation,may also
represent a second important limit. The third limitation is
that we included only males, so presently we cannot check
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for possible gender-related differences. Only through new
patient enrollment, of both sexes, we will be able to perform
protein expression quantification to study which specific
pathways/molecules drive RAGE expression in EAT as well
as clarify the existence of potential gender-related differences.
Finally, the comparison between EAT and other kinds of
fat depots, not performed in this study, could be helpful
to reinforce our data on the role of RAGE in linking EAT
metabolic dysfunction and CAD.
5. Conclusions
In conclusion this study’s findings suggest the potential
involvement of RAGE inpromotingEATdysfunction inCAD
patients. Whether RAGE could also be a potential target to
reduce EAT-induced cardiovascular and other complications
needs to be explored further.
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